ERBB2 and breast carcinoma: Our data demonstrate that HRG can activate the HER2 tyrosine kinase (not the serine or threonine kinase), thus leading to interaction between HER2 and FASN and subsequently inducing the tyrosine phosphorylation of FASN in human breast cancer cells.